Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Establishment of enhanced protein purification strategies for recombinant immunotherapeutics

Antibody-based diagnostic and therapeutic agents play a substantial role in modern medicine, particularly for cancer management. The use of monoclonal antibodies (mAbs) and their derivatives to fight cancer demonstrates a significant impact on both laboratory research and clinical applications. This...

Full description

Saved in:
Bibliographic Details
Main Author: Shangase, Valentine
Other Authors: Barth, Stefan
Format: Thesis
Language:English
English
Published: Department of Integrative Biomedical Sciences (IBMS) 2025
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613302156165120
access_status_str Open Access
author Shangase, Valentine
author2 Barth, Stefan
author_browse Barth, Stefan
Shangase, Valentine
author_facet Barth, Stefan
Shangase, Valentine
author_sort Shangase, Valentine
collection Thesis
description Antibody-based diagnostic and therapeutic agents play a substantial role in modern medicine, particularly for cancer management. The use of monoclonal antibodies (mAbs) and their derivatives to fight cancer demonstrates a significant impact on both laboratory research and clinical applications. This is largely attributed to their ability to recognize specific antigens. The enhancement of these well-characterized mAbs with effector molecules with desirable, tailored properties. This further gives the product to homogeneous antibody conjugates and improves their potency while reducing toxic side effects. An efficient and cost-effective protocol to produce high quality recombinant proteins play a pivotal role in supporting both lab-scale research and pharmaceutical applications. Although relying on the limited availability of resources, the MB&I research unit successfully employs a single IMAC step to purify mammalian and bacterially expressed recombinant proteins to successfully supporting a decent number of student projects per year. Such enriched protein preparation does allow preliminary qualitative analysis of such highly active immunotherapeutics; however, expanding this research into future readiness levels needs further expansion. The main objective of this study was to reestablish and develop an improved protein purification strategy by exploring Immobilized Metal Affinity Chromatography (IMAC), Ion Exchange Chromatography (IEX), and Size Exchange Chromatography (SEC) and further strategically integrating these purification techniques to improve protein purity. Intrinsic properties of the proteins of interest, such as the affinity tag incorporated in the recombinant antibody, and its Isoelectric value (pI), largely contribute to the choice of purification technique as demonstrated by the well characterized mammalian-expressed SNAP tag-based antibody fusion protein αASPH(scFv)-SNAP and the bacterially expressed recombinant immunotoxin 13 H22(scFv)-ETA. IMAC was employed as the initial purification step to recover the full-length histidine-tagged recombinant proteins. The Ni2+ immobilized on the matrices in columns has a high affinity for Histidine incorporated, which allows the capture of the target protein. The remaining host proteins were removed by IEX, which excludes charge-based impurity and isolates the target protein. SEC was used as the last polishing step to remove remaining aggregates and contaminants. Each purification strategy was independently enhanced by optimizing purification conditions such as the flow rate and the buffer system and subsequently integrated to achieve improved resolution. The data analysis showed that optimizing running conditions for each purification technique enhanced protein purity. A lower flow rate improved protein retention, thus reducing the loss of target protein. The buffer conditions also played a substantial role in achieving improved protein purity. The integrated purification strategy yielded a higher protein purity compared to the conventional single-step methods. on the contrary, a significant amount of the target protein is lost in each purification technique. An adaptable combinatory chromatography technique was established. The established purification workflow was successfully applied to a variety of other recombinant proteins. This was achieved by careful consideration of the unique physiochemical characteristics of recombinant protein. The established purification techniques can be expanded to a wider variety of fusion proteins. The protein purity and recovery following the application of the combinatory purification technique varied with the combination of chromatography and the nature of the protein. Bacterially expressed proteins require a more expensive wash step compared to mammalian-expressed proteins. However, higher protein yield was obtained from bacterially expressed proteins compared to mammalian-expressed proteins. The findings suggest that the choice of chromatography combination techniques should be based on the nature of the protein, yield, and purity requirement. MSc of Science (Medicine) ValenƟne Amanda Shangase The limited capacity to produce cost-effective recombinant immunotherapeutics significantly restricts the accessibility of antibody-based treatments such as monoclonal antibodies for cancer treatment. This study outlines the technology that can be a baseline for advancing lab-based research and local continuous production of recombinant biopharmaceuticals and offers a great opportunity to close the existing gap in developing countries.
format Thesis
id oai:open.uct.ac.za:11427/42316
institution University of Cape Town (South Africa)
language English
eng
last_indexed 2026-06-10T12:33:59.204Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2025
publishDateRange 2025
publishDateSort 2025
publisher Department of Integrative Biomedical Sciences (IBMS)
publisherStr Department of Integrative Biomedical Sciences (IBMS)
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/42316 Establishment of enhanced protein purification strategies for recombinant immunotherapeutics Shangase, Valentine Barth, Stefan Medicine Medical Biotechnology and Immunotherapy Antibody-based diagnostic and therapeutic agents play a substantial role in modern medicine, particularly for cancer management. The use of monoclonal antibodies (mAbs) and their derivatives to fight cancer demonstrates a significant impact on both laboratory research and clinical applications. This is largely attributed to their ability to recognize specific antigens. The enhancement of these well-characterized mAbs with effector molecules with desirable, tailored properties. This further gives the product to homogeneous antibody conjugates and improves their potency while reducing toxic side effects. An efficient and cost-effective protocol to produce high quality recombinant proteins play a pivotal role in supporting both lab-scale research and pharmaceutical applications. Although relying on the limited availability of resources, the MB&I research unit successfully employs a single IMAC step to purify mammalian and bacterially expressed recombinant proteins to successfully supporting a decent number of student projects per year. Such enriched protein preparation does allow preliminary qualitative analysis of such highly active immunotherapeutics; however, expanding this research into future readiness levels needs further expansion. The main objective of this study was to reestablish and develop an improved protein purification strategy by exploring Immobilized Metal Affinity Chromatography (IMAC), Ion Exchange Chromatography (IEX), and Size Exchange Chromatography (SEC) and further strategically integrating these purification techniques to improve protein purity. Intrinsic properties of the proteins of interest, such as the affinity tag incorporated in the recombinant antibody, and its Isoelectric value (pI), largely contribute to the choice of purification technique as demonstrated by the well characterized mammalian-expressed SNAP tag-based antibody fusion protein αASPH(scFv)-SNAP and the bacterially expressed recombinant immunotoxin 13 H22(scFv)-ETA. IMAC was employed as the initial purification step to recover the full-length histidine-tagged recombinant proteins. The Ni2+ immobilized on the matrices in columns has a high affinity for Histidine incorporated, which allows the capture of the target protein. The remaining host proteins were removed by IEX, which excludes charge-based impurity and isolates the target protein. SEC was used as the last polishing step to remove remaining aggregates and contaminants. Each purification strategy was independently enhanced by optimizing purification conditions such as the flow rate and the buffer system and subsequently integrated to achieve improved resolution. The data analysis showed that optimizing running conditions for each purification technique enhanced protein purity. A lower flow rate improved protein retention, thus reducing the loss of target protein. The buffer conditions also played a substantial role in achieving improved protein purity. The integrated purification strategy yielded a higher protein purity compared to the conventional single-step methods. on the contrary, a significant amount of the target protein is lost in each purification technique. An adaptable combinatory chromatography technique was established. The established purification workflow was successfully applied to a variety of other recombinant proteins. This was achieved by careful consideration of the unique physiochemical characteristics of recombinant protein. The established purification techniques can be expanded to a wider variety of fusion proteins. The protein purity and recovery following the application of the combinatory purification technique varied with the combination of chromatography and the nature of the protein. Bacterially expressed proteins require a more expensive wash step compared to mammalian-expressed proteins. However, higher protein yield was obtained from bacterially expressed proteins compared to mammalian-expressed proteins. The findings suggest that the choice of chromatography combination techniques should be based on the nature of the protein, yield, and purity requirement. MSc of Science (Medicine) ValenƟne Amanda Shangase The limited capacity to produce cost-effective recombinant immunotherapeutics significantly restricts the accessibility of antibody-based treatments such as monoclonal antibodies for cancer treatment. This study outlines the technology that can be a baseline for advancing lab-based research and local continuous production of recombinant biopharmaceuticals and offers a great opportunity to close the existing gap in developing countries. 2025-11-24T11:06:30Z 2025-11-24T11:06:30Z 2025 2025-11-24T11:03:36Z Thesis / Dissertation Masters MSc http://hdl.handle.net/11427/42316 en eng application/pdf Department of Integrative Biomedical Sciences (IBMS) Faculty of Health Sciences University of Cape Town
spellingShingle Medicine
Medical Biotechnology and Immunotherapy
Shangase, Valentine
Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
thesis_degree_str Master's
title Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
title_full Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
title_fullStr Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
title_full_unstemmed Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
title_short Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
title_sort establishment of enhanced protein purification strategies for recombinant immunotherapeutics
topic Medicine
Medical Biotechnology and Immunotherapy
url http://hdl.handle.net/11427/42316
work_keys_str_mv AT shangasevalentine establishmentofenhancedproteinpurificationstrategiesforrecombinantimmunotherapeutics